Anthropic, the developer of Claude, has quietly established a physical biology laboratory in the San Francisco Bay Area, US, as it expands its AI ambitions into pharmaceutical science. The facility, known as a wet lab, is dedicated to real-world experiments rather than just computational simulations.
In an interview, Eric Kauderer-Abrams, the company’s head of biological sciences, confirmed the lab’s existence, saying, “We believe that, for biology, the ultimate test remains—and will continue to be for a long time—real laboratory work.”
The company had previously announced plans to develop treatments for rare diseases, and its biology work now goes beyond purely virtual assessments (in silico). The approach combines internal experiments with external partnerships, similar to practices in many biotech companies.
A spokesperson clarified that the lab was not created specifically for drug discovery, but Anthropic signaled at a June event its intention to launch its own drug development programs. The focus will be on pre-clinical areas that traditional pharmaceutical companies find financially unattractive.
Recent initiatives include the launch of Claude Science software, the appointment of Novartis CEO Vas Narasimhan to its board, and the acquisition of startup Coefficient Bio for approximately $400 million in shares, according to press reports. Anthropic confirmed the purchase but did not disclose the exact amount.
CEO Dario Amodei revealed a personal motivation behind the effort: in a recent essay, he shared that his father died from a disease shortly before a cure was discovered.
Kauderer-Abrams also emphasized the company’s mission: “Anthropic’s mission is to develop powerful AI in a way that benefits the world. We see the greatest opportunity for this in the biological sciences, and that’s what drives everything we’re doing.”
Not competing with pharma companies—for now
Kauderer-Abrams said the company has set a clear boundary: it does not conduct clinical trials at present and focuses on unmet needs in the industry. “We are not competing with pharmaceutical and biotech companies that bring drugs to market,” he said.
Sources interviewed by Reuters suggest the move is part of a larger ambition: to address diseases neglected by the pharmaceutical industry before public trust in AI erodes due to job or life losses.
The success of any future drug program is not guaranteed, as most drugs fail safety and efficacy tests before reaching the market. Like other biotech companies, Anthropic already uses physical automation in its experiments.
Frequently Asked Questions
- What is the biology laboratory created by Anthropic?
It is a wet lab, a space for physical biology experiments, located in the San Francisco Bay Area, US.
- Why did Anthropic create a physical laboratory?
The company believes real experiments remain essential for validating biological research, as stated by its head of biological sciences.
- Does Anthropic intend to develop drugs?
Yes. The company has already announced plans to launch its own drug development programs, focusing on pre-clinical areas that are unattractive to traditional pharmaceutical companies.
- Does Anthropic conduct clinical trials of drugs?
No. The company stated it does not conduct clinical trials at present and focuses on unmet needs in the industry.
- What investments has Anthropic already made in biology?
It launched Claude Science, appointed Vas Narasimhan to its board, and acquired the startup Coefficient Bio for approximately $400 million in shares.
- What is Anthropic’s goal in the biological sciences?
To apply artificial intelligence to the study of rare diseases and other neglected conditions, using AI to benefit society.
